Our mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets.
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil.
We are very pleased to be able to bring Suprax® an important anti-infective product in pediatric practice, back to the US market.
We are recognized as a leading manufacturer of cephalosporin API's, with FDA approval to manufacture complex oral and injectable cephalosporins.
Lupin is amongst the world's largest manufacturers of products in its chosen therapeutic areas.
Lupin launches first ever Duloxetine 40mg Delayed-Release Capsules in the US
Lupin receives FDA approval for Fenofibrate Tablets, 54 mg and 160 mg
Lupin Announces New Center of Excellence for Inhalation Research in Florida
Lupin Acquires Specialty Product Portfolio in Germany
Lupin Acquires GAVIS to Expand US Generic Business
Lupin Acquires Biocom in Russia
Lupin Acquires Medquimica in Brazil
Lupin Launches Generic Exforge® Tablets in the US
manufacturing / r&d
Copyright © 2010, Lupin Pharmaceuticals, Inc., All Rights Reserved.